Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00108-023-01480-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chlorthalidone vs Hydrochlorothiazide and Kidney Outcomes in Patients With Hypertension: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Netw Open
December 2024
Cooperative Studies Program Coordinating Center, VA Boston Healthcare System, Boston, Massachusetts.
Importance: Hypertension is a risk factor for the development and progression of chronic kidney disease (CKD). It is unclear whether different thiazide diuretics have a differential impact on kidney outcomes.
Objective: To compare kidney outcomes in patients with hypertension taking chlorthalidone and hydrochlorothiazide.
Thiazide and thiazide-like diuretics are associated with improved cardiovascular and renal outcomes in patients with chronic kidney disease.
Ann Acad Med Singap
October 2023
Department of Pediatrics, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Taiwan.
Introduction: Hypervolemia is a prevalent comorbidity of chronic kidney disease (CKD) patients. Thiazide diuretics (THZ) are the most common treatment for volume overload and hypertension (HTN). This study examines the association between THZ usage and clinical outcomes among CKD patients in a nationwide cohort.
View Article and Find Full Text PDFMechanisms of Antihypertensive Effect of Chlorthalidone in Advanced Chronic Kidney Disease: A Causal Mediation Analysis.
Clin J Am Soc Nephrol
August 2024
Department of Biostatistics and Health Data Science, Richard M. Fairbanks School of Public Health, Indiana University Center for Aging Research, Indiana University School of Medicine, Regenstrief Institute, Indianapolis, Indiana.
Key Points: Chlorthalidone reduces the amount of fluid and the BP, but fluid volume reduction is not the cause of lowering of BP. It is not volume loss but the response to volume loss such as the synthesis of substances that lower BP is important.
Background: Chlorthalidone (CTD) in a chronic kidney disease randomized trial demonstrated a robust reduction in systolic BP in stage 4 CKD.
Top studies of 2023 relevant to primary care: From the PEER team.
Can Fam Physician
April 2024
Director of Programs and Practice Support at the CFPC.
Article Synopsis
- The objective was to summarize important medical articles from 2023 that are relevant for family physicians.
- The articles were selected and ranked by the PEER team, focusing on evidence-based medicine and monitoring high-impact medical journals for useful research.
- Key topics covered include lipid management, cardiovascular outcomes, vaccines for older adults, and new medications like retatrutide and fezolinetant, all relevant to primary care practice.
The thiazide-like diuretic chlorthalidone as an alternative evidence-based therapy for resistant hypertension in patients with stage 4 chronic kidney disease.
Expert Rev Clin Pharmacol
May 2024
2nd Department of Nephrology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!